NCT05336032 is a NA clinical trial of Food (rice) in Glycemic Response, sponsored by Rashid Centre for Diabetes and Research.

Who is sponsoring NCT05336032?

NCT05336032 is sponsored by Rashid Centre for Diabetes and Research.

What drugs are being tested in NCT05336032?

Interventions in NCT05336032: Food (rice).

What condition does NCT05336032 study?

NCT05336032 studies Glycemic Response.

Is NCT05336032 still recruiting?

NCT05336032 is currently status unknown. Last updated 26 October 2022.

Last reviewed 2022-10-26 · How we verify

NCT05336032

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ethnic Variability in Glycemic and Hunger Satiety Response to Rice in Overweight Adults

Status unknown NA Last updated 26 October 2022

What this trial tests

NA trial testing Food (rice) in Glycemic Response in 20 participants. Status unknown.

Timeline

1 April 2022

Primary endpoint
30 August 2022

30 October 2022

Quick facts

Lead sponsor	Rashid Centre for Diabetes and Research
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	diagnostic
Enrollment	20
Start date	1 April 2022
Primary completion	30 August 2022
Estimated completion	30 October 2022
Sites	1 location across United Arab Emirates

Drugs / interventions tested

Food (rice)

Conditions studied

Glycemic Response — all drugs for Glycemic Response →

Sponsor

Rashid Centre for Diabetes and Research

Who can join

Adults 18 to 55, any sex, with Glycemic Response. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evidence has./ indicated increased risk of type 2 diabetes with white rice consumption in Asian population. It is shown that glycemic response to carbohydrate-containing food may differ in people of different ethnicities. The large increment in glucose concentration induced by high glycemic index food often exaggerates the body's anabolic responses, which facilitates the overproduction of insulin and eventually results in pancreatic beta-cell failure, causing type 2 diabetes mellitus. Given that rice is the staple food of Asians and Emiratis, and extent to which rice influences postprandial glycemia could have potential relevance in the prevention and treatment of diabetes. In this study, the investigators intend to compare the glycemic and hunger satiety response to rice among overweight Emiratis, Asians, and Caucasian. The primary objective of the study is to compare the glycemic (glucose) and hunger satiety (hormone ghrelin and peptide YY) response to glucose and rice among overweight Emiratis, Asians, and Caucasians.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ethnic Variability in Glucose and Insulin Response to Rice Among Healthy Overweight Adults: A Randomized Cross-Over Study.
Sadiya A, Jakapure V, Kumar V. · · 2023 · cited 6× · PMID 37063254 · DOI 10.2147/dmso.s404212

Verify or expand the search:

Other recruiting trials for Glycemic Response

Currently open trials in the same condition.

NCT04881019 — PRediction Of Glycemic RESponse Study · active not recruiting

Other Rashid Centre for Diabetes and Research trials

Trials by the same sponsor.

NCT04273412 — Lifestyle Intervention for Prevention of Gestational Diabetes Mellitus in the UAE Population · NA · completed
NCT03388229 — Association Between Dietary Pattern and Glycemic Control Among Type 2 Diabetes Patients in the Unites Arab Emirates · completed
NCT03644134 — A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05336032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rashid Centre for Diabetes and Research
Last refreshed: 26 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05336032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing